BCM
PNT

Bayesian Capital Management’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Bayesian Capital Management’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,962
Closed -$116K – 1092
2022
Q3 		$116K Buy
+14,962
New +$127K 0.02% 582

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bayesian Capital Management's PNT Position: Q4 2022 in Review

Bayesian Capital Management sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2022, closing a stake of 14,962 shares — an estimated $116K sold.

Bayesian Capital Management first reported a position in PNT in Q3 2022 and held it in 1 quarter. The position peaked at $116K in Q3 2022. 109 funds tracked by Wall St. Rank hold PNT as of Q4 2022.

  • Bayesian Capital Management reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 14,962 POINT Biopharma Global Inc. Common Stock shares in Q4 2022, an estimated $116K.
  • Bayesian Capital Management first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Bayesian Capital Management's POINT Biopharma Global Inc. Common Stock position peaked at $116K in Q3 2022.
  • 109 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2022.

Based on Bayesian Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.